Myrzaliev B, Ahmatov M, Duishekeeva A, Kulzhabaeva A, Kadyrov A, Toktogonova A, Abdulaeva G, Wares D F, Mirtskhulava V, Mbenga M, Slyzkyi A, Foraida S, Diachenko M, Juneja S, Turdumambetova G, Musaeva A, Gebhard A
KNCV Tuberculosis Foundation, The Hague, The Netherlands.
I K Ahunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.
J Clin Tuberc Other Mycobact Dis. 2024 Jul 26;36:100472. doi: 10.1016/j.jctube.2024.100472. eCollection 2024 Aug.
In Kyrgyzstan, drug-resistant tuberculosis poses a significant challenge. Recognizing the potential of the BPaL regimen, the World Health Organization recommended its use for selected drug-resistant TB cases under operational research conditions in 2020.
This report presents experiences and results from the BPaL operational research under the LIFT-TB project in Kyrgyzstan.
Prospective cohort study.
From August 2021 to June 2022, 50 patients were enrolled, achieving an 84 % treatment success rate. Although adverse events affected 11 patients (34.3 %), primarily linked to linezolid use (39 [78 %] patients started on 1200 mg linezolid daily), no unexpected adverse events occurred, and management was appropriate. The operational research emphasized proper patient inclusion, highlighting the crucial roles of psychological counselling support and active drug safety monitoring.
With insights gained, Kyrgyzstan is now nationwide implementing the BPaLM/BPaL regimens for a broader drug-resistant TB patient group. The experiences, successes, and lessons from the BPaL operational research, along with the programmatic introduction, offer valuable guidance for global drug-resistant TB control strategies. This initiative becomes a resource for countries with similar drug-resistant TB burdens, promoting a collaborative global approach to address drug-resistant TB challenges.
在吉尔吉斯斯坦，耐药结核病构成了重大挑战。认识到BPaL方案的潜力，世界卫生组织于2020年建议在运营研究条件下将其用于选定的耐药结核病病例。
本报告介绍了吉尔吉斯斯坦LIFT-TB项目下BPaL运营研究的经验和结果。
前瞻性队列研究。
2021年8月至2022年6月，共纳入50例患者，治疗成功率达到84%。尽管有11例患者（34.3%）出现不良事件，主要与利奈唑胺的使用有关（39例[78%]患者开始每日使用1200mg利奈唑胺），但未发生意外不良事件，且管理得当。运营研究强调了正确纳入患者，突出了心理咨询支持和积极药物安全监测的关键作用。
基于所获得的见解，吉尔吉斯斯坦目前正在全国范围内为更广泛的耐药结核病患者群体实施BPaLM/BPaL方案。BPaL运营研究的经验、成功之处和教训，以及方案的引入，为全球耐药结核病控制策略提供了宝贵的指导。这一举措成为耐药结核病负担相似国家的一种资源，促进了应对耐药结核病挑战的全球协作方法。
